Cancer Prevention pp 219-224 | Cite as
Angiogenesis and Cancer Prevention: A Vision
Abstract
Angiogenesis is necessary for solid tumor growth and dissemination. In addition to angiogenesis, it has become increasingly clear that inflammation is a key component in cancer insurgence that can promote tumor angiogenesis. We noted that angiogenesis is a common and key target of most chemopreventive molecules, where they most likely suppress the angiogenic switch in premalignant tumors, a concept we termed angioprevention. We have shown that various molecules, such as flavonoids, antioxidants, and retinoids, act in the tumor microenvironment, inhibiting the recruitment and/or activation of endothelial cells and phagocytes of the innate immunity. N-acetyl-cysteine, and the green tea flavonoid epigallocatechin-3-gallate (EGCG) and the beer/hops-derived chalcone Xanthohumol all prevent angiogenesis in the Matrigel sponge angiogenic assay in vivo and inhibit the growth of the highly angiogenic Kaposi’s sarcoma tumor cells (KS-Imm) in nude mice. The synthetic retinoid 4-hydroxyfenretinide (4HPR) also shows antiangiogenic effects. We analyzed the regulation of gene expression they exert in primary human umbilical endothelial cells (HUVEC) in culture with functional genomics. Expression profiles obtained through Affymetrix GeneChip arrays identified overlapping sets of genes regulated by anti-oxidants. In contrast, the ROS-producing 4HPR induced members of the TGFβ-ligand superfamily, which, at least in part, explains its anti-angiogenic activity. NAC and the flavonoids all suppressed the IkB/NF-κB signaling pathway even in the presence of NF-κB stimulation by TNFα, and showed reduced expression of many NF-κB target genes. A selective apoptotic effect on transformed cells, but not on endothelial cells, of the anti-oxidants may be related to the reduced expression of the NF-κB-dependent survival factors Bcl2 and Birc5/surviving, which are selectively overexpressed in transformed cells by these factors. The repression of the NF- κB pathway suggests anti-inflammatory effects for the antioxidant compounds that may also represent an indirect role in angiogenesis inhibition. The green tea flavonoid EGCG does target inflammatory cells, mostly neutrophils, and inhibits inflammation-associated angiogenesis. The other angiopreventive molecules are turning out to be effective modulators of phagocyte recruitment and activation, further linking inflammation and vascularization to tumor onset and progression and providing a key target for cancer prevention.
Keywords
Antiangiogenic Activity Angiogenic Switch Solid Tumor Growth Promote Tumor Angiogenesis Hyperplastic FocusPreview
Unable to display preview. Download preview PDF.
References
- Aggarwal BB, Shishodia S (2004). Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann N Y Acad Sci 1030:434–441PubMedCrossRefGoogle Scholar
- Albini A, Noonan DM (2005) Rescuing COX-2 Inhibitors From the Waste Bin. J Natl Cancer Inst 97:859–860PubMedCrossRefGoogle Scholar
- Albini A, Tosetti F, Benelli R, Noonan DM (2005) Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 65:10637–10641PubMedCrossRefGoogle Scholar
- Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRefGoogle Scholar
- Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211–217PubMedCrossRefGoogle Scholar
- Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, Cassatella M, Noonan DM, Albini A (2002) Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 16:267–269PubMedGoogle Scholar
- Benelli R, Albini A, Noonan D (2003) Neutrophils and angiogenesis: potential initiators of the angiogenic cascade. In: The neutrophil: Cassatella MA (ed) An emerging regulator of inflammatory and immune response. Karger, Basel pp 167–181CrossRefGoogle Scholar
- Benelli R, Frumento G, Albini A, Noonan DM (2006a) Models of inflammatory processes in cancer. In: Marshall LA, Stevenson CS, Morgan DW (eds) In vivo models of inflammation. Birkhäuser, Basel, pp 83–102CrossRefGoogle Scholar
- Benelli R, Lorusso G, Albini A, Noonan DM (2006b) Cytokines and Chemokines as regulators of angiogenesis in health and disease. Curr Pharm Des 12:3101–3115PubMedCrossRefGoogle Scholar
- Brigati C, Noonan DM, Albini A, Benelli R (2002) Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 19:247–258PubMedCrossRefGoogle Scholar
- Brown JR, DuBois RN (2005) COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23:2840–2855PubMedCrossRefGoogle Scholar
- Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932–936PubMedCrossRefGoogle Scholar
- Coussens LM, Werb Z (2001) Inflammatory cells and cancer: think different! J Exp Med 193:F23–F26PubMedCrossRefGoogle Scholar
- Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCrossRefGoogle Scholar
- Dell’Eva R, Ambrosini C, Minghelli S, Noonan DM, Albini A, Ferrari N (2006) The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-{kappa} B pathway. Carciogenesis, in pressGoogle Scholar
- Dorai T, Aggarwal BB (2004) Role of chemopreventive agents in cancer therapy. Cancer Lett 215:129–140PubMedCrossRefGoogle Scholar
- Dvorak HF (2005) Angiogenesis: update 2005. J Thromb Haemost 3:1835–1842PubMedCrossRefGoogle Scholar
- Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967–974PubMedCrossRefGoogle Scholar
- Ferrari N, Pfeffer U, Dell’Eva R, Ambrosini C, Noonan DM, Albini A (2005) The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl) retinamide. Clin Cancer Res 11:4610–4619PubMedCrossRefGoogle Scholar
- Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedCrossRefGoogle Scholar
- Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRefGoogle Scholar
- Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62PubMedCrossRefGoogle Scholar
- Karin M (2005) Inflammation and cancer: the long reach of Ras. Nat Med 11:20–21PubMedCrossRefGoogle Scholar
- Karin M, Greten FR (2005) NF-kappaB: linking in-flammation and immunity to cancer development and progression. Nat Rev Immunol 5:749–759PubMedCrossRefGoogle Scholar
- Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727–739PubMedCrossRefGoogle Scholar
- Pfeffer U, Ferrari N, Dell’eva R, Indraccolo S, Morini M, Noonan DM, Albini A (2005) Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: Microarray gene expression analyses. Mutat Res 591:198–211PubMedGoogle Scholar
- Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71–78PubMedCrossRefGoogle Scholar
- Rafii S, Lyden D, Benezra R, Hattori K, Heissig B (2002) Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826–835PubMedCrossRefGoogle Scholar
- Scapini P, Morini M, Tecchio C, Minghelli S, Carlo ED, Tanghetti E, Albini A, Lowell C, Berton G, Noonan DM, Cassatella MA (2004) CXCL1/Macrophage Inflammatory Protein-2-Induced Angiogenesis in Vivo is Mediated by Neutrophil-Derived Vascular Endothelial Growth Factor-A1. J Immunol 172:5032–5040Google Scholar
- Sparmann A, Bar-Sagi D (2004) Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6:447–458PubMedCrossRefGoogle Scholar
- Tosetti F, Ferrari N, De Flora S, Albini A (2002) Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16:2–14PubMedCrossRefGoogle Scholar